Have a personal or library account? Click to login
Photochemical toxicity of drugs intended for ocular use Cover

Photochemical toxicity of drugs intended for ocular use

Open Access
|Jun 2014

References

  1. 1. Organisation for Economic Cooperation and Development (OECD). Guidelines for the Testing of Chemicals No. 405: Acute Eye Irritation/Corrosion. Paris: OECD; 2002.
  2. 2. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002;53:263-80. doi: 10.1016/S0939-6411(01)00246-610.1016/S0939-6411(01)00246-6
  3. 3. Benavides T, Martínez V, Mitjans M, Infante MR, Moran C, Clapés P, Clothier R, Vinardell MP. Assessment of the potential irritation and photoirritation of novel amino acidbased surfactants by in vitro methods as alternative to the animal tests. Toxicology 2004;201:87-93. doi: 10.1016/j. tox.2004.04.003
  4. 4. ICCVAM Test Method Evaluation Report: Appendix G-ICCVAM Recommended HET-CAM Test Method Protocol, 2006 [displayed 2 May 2014]. Available at http://ntp.niehs.nih.gov/iccvam/docs/ocutox_docs/oteval/appg-508.pdf
  5. 5. ICCVAM-Recommended Protocol for Using the Isolated Chicken Eye (ICE) Test Method Protocol, 2012 [displayed 2 May 2014]. Availalble at http://ntp.niehs.nih.gov/iccvam/docs/protocols/iceprotocol16jul12v2-508.pdf
  6. 6. Organisation for Economic Cooperation and Development (OECD). Guidelines for the Testing of Chemicals No 438: Isolated Chicken Eye Test Method for Identifying Ocular Corrosives and Severe Irritants. Paris: OECD; 2009.
  7. 7. Velpandian T, Bankoti R, Humayun S, Ravi AK, Kumari SS, Biswas NR. Comparative evaluation of possible ocular photochemical toxicity of fluoroquinolones meant for ocular use in experimental models. Indian J Exp Biol 2006;44:387-91. PMID: 16708892
  8. 8. INVITTOX Protocol No 37, European Centre for the Validation of Alternative Methods RBC Test System, Ispra: ECVAM DB-ALM; 2010.
  9. 9. Editors. Artifacts of light. Nat Meth. 2013;10:1135. doi: 10.1038/nmeth.276010.1038/nmeth.2760
  10. 10. Ahmad T, Ahmed I. Multicomponent spectrophotometric assay of sulphacetamide and photodegradation products. Pak J Pharm Sci 1990;3:29-39. PMID:16414659
  11. 11. Miyazaki T, Yomota C, Okada S. Depolymerization of hyaluronate by the phototoxic drugs phenothiazines and sulphacetamide. Colloid Polymer Sci 2000;278:84-9. doi: 10.1007/s00396005001410.1007/s003960050014
  12. 12. Jordan L. Holtzman. Role of reactive oxygen and metabolite binding in drug toxicity. Life Sci 1982;30:1-9. doi: 10.1016/0024-3205(82)90629-410.1016/0024-3205(82)90629-4
  13. 13. Mhaske RA, Sahasrabudhe S. Identification of Major Degradation Products of Ketoconazole. Sci Pharm 2011;79:817-36. doi: 10.3797/scipharm.1107-1810.3797/scipharm.1107-18
  14. 14. Mohamed KN. Severe photodermatitis during ketoconazole therapy. Clin Exp Derm 1988;13:54. PMID: 320844410.1111/j.1365-2230.1988.tb00654.x
  15. 15. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new antifungal agent, in human liver microsomes. Biochem Pharmacol 2007;73:2020-6. doi: 10.1111/j.1365-2125.2009.03534.x10.1111/j.1365-2125.2009.03534.x
  16. 16. Vogna D, Marotta R, Napolitano A, Andreozzi R, d’Ischia M. Advanced oxidation of the pharmaceutical drug diclofenac with UV/H2O2 and ozone. Water Res 2004;38:414-22. doi: 10.1016/j.watres.2003.09.02810.1016/j.watres.2003.09.028
  17. 17. Roberts JE. Ocular phototoxicity. J Photochem Photobiol B 2001;64:136-43. doi: 10.1016/S1011-1344(01)00196-810.1016/S1011-1344(01)00196-8
  18. 18. Motten AG, Chignell CF. Spectroscopic studies of cutaneous photosensitizing agents-III. Spin trapping of photolysis products from sulphanilamide analogs. Photochem Photobiol 1983;37:17-26. PMID: 630094010.1111/j.1751-1097.1983.tb04428.x6300940
  19. 19. Staub I, Flores L, Gosmann G, Pohlmann A, Fröehlich PE, Schapoval EES, Bergold AM. Photostability studies of ketoconazole: isolation and structural elucidation of the main photodegradation products. Latin Am J Pharm 2010;29:1100-6.
  20. 20. Adams AIH, Grace G, Paulo HS, Ana MB. LC stability studies of voriconazole and structural elucidation of its major degradation product. Chromatographia 2009;69(Supplement):115-22. doi: 10.1365/s10337-009-1082-310.1365/s10337-009-1082-3
  21. 21. Epaulard O, Saint-Raymond C, Villier C, Charles J, Roch N, Beani JC, Leccia MT. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect 2010;16:1362-4. doi: 10.1111/j.1469-0691.2009.03124.x10.1111/j.1469-0691.2009.03124.x
  22. 22. Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15. doi: 10.1111/j.1365-2125.2009.03534.x10.1111/j.1365-2125.2009.03534.x
  23. 23. Encinas S, Bosca F, Miranda MA. Phototoxicity associated with diclofenac: a photophysical, photochemical, and photobiological study on the drug and its photoproducts. Chem Res Toxicol 1988;11:946-52. doi: 10.1021/tx980070810.1021/tx9800708
  24. 24. Leo G, Hi-Shi C, Johanson D. Light degradation of ketorolac tromethamine. Int J Pharmaceutics 1988;41:105-13. doi:10.1016/0378-5173(88)90142-1. 10.1016/0378-5173(88)90142-1
DOI: https://doi.org/10.2478/10004-1254-65-2014-2461 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 157 - 167
Submitted on: Nov 1, 2013
Accepted on: Apr 1, 2014
Published on: Jun 17, 2014
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2014 Roshan Kumar Sahu, Bhupendra Singh, Shubhini A. Saraf, Gaurav Kaithwas, Kamal Kishor, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.